Findings show miR-6134 and IL-6 may improve diagnostic tools for malignant ovarian tumors.
The combination of miR-6134, CA125, HE4, and IL-6, or miR-6134 alone, shows potential as a serum biomarker for EOC, particularly in distinguishing malignant from benign ovarian tumors. The combination of two miRNAs also demonstrated high discriminative power in cases with CA125 below the cutoff. These findings may contribute to the development of improved non-invasive diagnostic tools and warrant further validation.
No takes yet. Share an insight, caveat, or question.
Kawahara et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: